NOT-HL-19-736: Notice of Frequently Asked Questions for RFA-HL-20-014 "Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed)"

Notice of Frequently Asked Questions for RFA-HL-20-014 "Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed)"

Notice Number: NOT-HL-19-736

Key Dates
Release Date: December 19, 2019

Related Announcements
RFA-HL-20-014

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the NHLBI has posted a set of Frequently Asked Questions (FAQs) regarding applications for RFA-HL-20-014 "Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed)”.

The FAQs are available at this site:

https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/all-funding-opportunity-announcements/RFA-HL-20-014

Although not required for application, applicants are strongly encouraged to review the FAQs (which may be updated at any time without additional notice) prior to submitting their application.

Inquiries

Please direct all inquiries to:

Andrei Kindzelski, MD, PhD
Division of Blood Diseases and Resources
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0050
Email: [email protected]

Lora Reineck, MD, MS
Division of Lung Diseases
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0222
Email: [email protected]

Michelle Olive, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-443-7933
Email: [email protected]